Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $214.20 | Total: $1,071.00 |
| 1 | 10 | $181.44 | Total: $1,814.40 |
| 1 | 25 | $153.72 | Total: $3,843.00 |
| 1 | 50 | $131.04 | Total: $6,552.00 |
| 1 | 100 | $113.40 | Total: $11,340.01 |
Overview
BMS-593214 is an active site-directed factor (F) VIIa inhibitor that exhibits antithrombotic and antihaemostatic properties. It acts as a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of FVIIa-activated substrate FX. Additionally, BMS-593214 effectively prevents electroinduced carotid artery thrombosis (AT) and wire-induced vena cava thrombosis (VT).
Chemical Properties
| Molecular Formula | C31H27N3O4 |
| Molecular Weight | 505.56 |
| CAS Numbers | 1004551-40-9 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(=N)(N)C=1C=C2[C@@]3([C@]([C@@H](NC2=CC1)C4=C(C=C(O)C(OC)=C4)C5=CC=C(C(O)=O)C=C5)(CC=6C3=CC=CC6)[H])[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrobial Agents and Chemotherapy [2012], 56[7], 3498-3507.